JP Morgan Initiates Coverage On Kura Oncology with Overweight Rating, Announces Price Target of $30

JP Morgan analyst Priyanka Grover has initiated coverage on Kura Oncology (NASDAQ: KURA) with an Overweight rating. The firm has set a price target of $30 for the company's stock.